NewAmsterdam Pharma Co N.V. SEC filings NAMS

NewAmsterdam Pharma Co N.V. has 415 filings in SEC EDGAR's recent list, going back to Aug 4, 2022. Its latest annual report, Form ARS, was filed on May 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.

NewAmsterdam Pharma Co N.V. SEC filings
Form Description Filed Period
ARS Annual report to shareholders May 6, 2026 Dec 31, 2025
10-K Annual report Feb 18, 2026 Dec 31, 2025
ARS Annual report to shareholders May 8, 2025 Dec 31, 2024
10-K Annual report Feb 26, 2025 Dec 31, 2024
20-F/A Amended annual report (foreign issuer) Oct 28, 2024 Dec 31, 2022
ARS Annual report to shareholders May 9, 2024 Dec 31, 2023
10-K Annual report Feb 28, 2024 Dec 31, 2023
20-F Annual report (foreign issuer) Mar 31, 2023 Dec 31, 2022
20-F Annual report (foreign issuer) Nov 28, 2022 Nov 22, 2022

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NAMS (Nasdaq), NAMSW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Netherlands
Headquarters
Narrden, Netherlands
SEC filer status
Large accelerated filer
SEC CIK
1936258
Former names
NewAmsterdam Pharma Co B.V. (until Nov 22, 2022)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.